myocardial ischemia market research, myocardial ischemia market growth forecast, myocardial ischemia industry share, myocardial ischemia market top keyplayers, myocardial ischemia market outlook, global myocardial ischemia market
What is the present valuation and projected CAGR of the myocardial ischemia market?
The myocardial ischemia market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.85 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to utilization of telemedicine and remote monitoring, development of novel reperfusion therapies for mi, increased cases of obesity, increased cases of high blood pressure, increase in cases of heart attacks.
The myocardial ischemia market size is expected to see strong growth in the next few years. It will grow to $1.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to prevalence of various heart-related diseases, growing awareness of the population about cardiovascular diseases, constantly changing lifestyles of people, rising cases of diabetes, rising healthcare expenditure. Major trends in the forecast period include adoption of myocardial ischemia treatments, better healthcare infrastructures, advancements in treatment options, integration of digital health solutions, launches of cardiac rehabilitation programs.
Get Your Free Sample of The Global Myocardial Ischemia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16488&type=smp
Which Market drivers have played a significant role in driving the myocardial ischemia market?
The rising incidence of diabetes is expected to propel the growth of the myocardial ischemia market going forward. Diabetes refers to a group of metabolic disorders that involve the body’s inability to produce or effectively use insulin, a hormone produced by the pancreas that regulates blood sugar levels. The rising incidence of diabetes is due to obesity and severe obesity, a lack of physical activity, and genetic factors. The growing prevalence of diabetes contributes to the higher incidence of myocardial ischemia, leading to increased demand for diagnostic, therapeutic, and management solutions for myocardial ischemia. For instance, in April 2023, according to a report published by The British Diabetic Association, a UK-based diabetes charity, 4.3 million individuals in the UK were diagnosed with diabetes. Registration data for 2021-22 shows an increase of 148,951 cases compared to 2020-21. Additionally, over 2.4 million people in the UK are at high risk of developing type 2 diabetes. The rising incidence of diabetes is driving the growth of the myocardial ischemia market.
What are the key segments within the myocardial ischemia market?
The myocardial ischemia market covered in this report is segmented –
1) By Type: Symptomatic, Asymptomatic
2) By Treatment And Diagnosis: Diagnosis, Treatment
3) By End User: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgery Centers
Subsegments:
1) By Symptomatic: Acute Myocardial Ischemia, Chronic Myocardial Ischemia, Stable Angina, Unstable Angina
2) By Asymptomatic: Silent Myocardial Ischemia, Exercise-Induced Asymptomatic Ischemia
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report
Which key players are shaping the myocardial ischemia market?
Major companies operating in the myocardial ischemia market are Cardinal Health Inc., Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories Inc., Eli Lilly and Company, Novo Nordisk A/S, Medtronic Plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Siemens Healthineers AG, Merck KGaA, GE HealthCare Technologies Inc., Fujifilm Holdings Corporation, Baxter International Inc., Regeneron Pharmaceuticals Inc., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Canon Medical Systems Corporation
Which transformative trends will shape the myocardial ischemia market landscape?
Major companies operating in the myocardial ischemia market are developing innovative drugs such as Lodoco (colchicine) to reduce inflammation and lower the risk of cardiovascular events in patients with coronary artery disease. Lodoco is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. For instance, in June 2023, Agepha Pharma, a US-based pharmaceutical company, launched Lodoco (colchicine), approved by the Food and Drug Administration, a US-based government agency. This approval marks the first FDA-approved treatment targeting cardiovascular inflammation. It is based on data from the LoDoCo2 trial, which demonstrated a 31% relative reduction in the risk of cardiovascular events with colchicine 0.5 mg once daily compared to placebo. Lodoco is prescribed to lower the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or multiple cardiovascular risk factors.
How do regional factors impact the myocardial ischemia market, and which region is the largest contributor?
North America was the largest region in the myocardial ischemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial ischemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Myocardial Ischemia Market Report 2025 Offer?
The myocardial ischemia market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Myocardial ischemia, also known as cardiac ischemia, is a condition characterized by reduced blood flow to the heart muscle. This reduction in blood flow leads to inadequate oxygen and nutrient delivery to the heart, potentially causing damage to the heart muscle. The most common cause of myocardial ischemia is the buildup of plaque in the coronary arteries, which restricts blood flow.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16488
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
